Insights Into Diffuse Large B-Cell Lymphoma (DLBCL) 2025
Perspectives on drivers in treatment decisions in the management of DLBCL, perception of various therapeutics, and understanding of the current and future treatment landscape
Southeast – March 22, 2025
Faculty Chair
Amitkumar Mehta, MD
University of Alabama, Birmingham, AL, USA
Central – April 5, 2025
Faculty Chair
Matthew Lunning, DO, FACP
University of Nebraska Medical Center, Omaha, NE, USA
DC – June 28, 2025
Faculty Chair
Nilanjan Ghosh, MD
Wake Forest University School of Medicine, Winston-Salem, NC, USA
Florida – August 9, 2025
Faculty Chair
Alan Kerr, MD, PhD
Cancer Center of South Florida, Palm Springs, FL, USA
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Dallas, TX
- Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas
More Information
- Phoenix, AZ
- Arizona, Colorado, Nevada, New Mexico, Southern California, Utah
More Information
- VA
- DC (Virginia side)
More Information
- Orlando, FL
- Florida
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of DLBCL
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: rituximab, lenalidomide, obinutuzumab, idelalisib, bortezomib, ibrutinib, axicabtagene ciloleucel, and polatuzumab vedotin
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
